BIONDVAX PHARMACEUTICALS-ADR (BVXV) Earnings History & Surprises
NASDAQ:BVXV • US09073Q2049
1.36 USD
+0.05 (+3.82%)
At close: Sep 6, 2023
1.38 USD
+0.02 (+1.47%)
After Hours: 9/6/2023, 8:00:01 PM
Past quarterly earnings results for BIONDVAX PHARMACEUTICALS-ADR (BVXV), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateN/A
PeriodQ3 / 2023
EPS Estimate-$1.01
Revenue Estimate
Last Reported
Release DateAug 11, 2023
PeriodQ2 / 2023
EPS Reported-$1.11
EPS Surprise -19.59%
Revenue Surprise %
Beat Rate
0%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2023 | -1.11 | -0.93 | -19.59% | -455.00% | - | - | ||
| Q1 2023 | -1.09 | -0.74 | -46.39% | 45.50% | - | - | ||
| Q4 2022 | -0.10 | - | 96.22% | - | - | |||
| Q3 2022 | 0.01 | -0.10 | 109.80% | - | - | - | ||
| Q2 2022 | -0.20 | -1.07 | 81.33% | -519.22% | - | - | ||
| Q1 2022 | -2.00 | -1.02 | -96.08% | -12,272.16% | - | - | ||
| Q4 2021 | -2.70 | -0.87 | -211.42% | -29,900.00% | - | - | ||
| Q3 2021 | - | - | - | - | ||||
| Q2 2021 | -0.03 | - | 99.72% | - | - | |||
| Q1 2021 | -0.02 | - | 98.38% | - | - | |||
| Q4 2020 | -0.01 | -0.01 | 11.76% | - | - | - | ||
| Q3 2020 | -0.01 | -0.01 | 1.96% | - | - | - | ||
| Q2 2020 | -11.40 | -0.10 | -11,076.47% | - | - | - | ||
| Q1 2020 | -1.00 | -0.10 | -880.39% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
48.25%
Max EPS beat (4)
109.80%
Min EPS beat (4)
-46.39%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, BVXV has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, BVXV has beaten the EPS estimates by 48.2% on average.
BIONDVAX PHARMACEUTICALS-ADR / BVXV Earnings FAQ
When did BIONDVAX PHARMACEUTICALS-ADR (BVXV) report earnings last quarter?
BIONDVAX PHARMACEUTICALS-ADR (BVXV) last reported earnings on 8/11/2023.
Did BIONDVAX PHARMACEUTICALS-ADR (BVXV) beat earnings estimates last quarter?
BIONDVAX PHARMACEUTICALS-ADR (BVXV) missed EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often BIONDVAX PHARMACEUTICALS-ADR beats earnings estimates?
In the last 4 quarters, BIONDVAX PHARMACEUTICALS-ADR (BVXV) has beaten EPS estimates in 2 out of 4 releases.